Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options

Jan 10 2019

• By Sue Sutter

Foot of gout patient.Close up Painful and inflamed gout. - Image

Related Content

Waiting For Next Regulatory Shoe To Drop For Takeda's Gout Drug Uloric

Mar 30 2018

Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating

Jan 08 2019

Drug Safety Announcement Blitz Highlights Gottlieb's PR Savvy As Shutdown Drags On

Jan 10 2019

Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population

Oct 18 2018

Diabetes Drugs: Longer, Broader Phase II/III Trials Could Replace CV Outcomes Trials, US Panel Says

Oct 26 2018

Score One For FDAAA: Uloric Approval Was Clinched By Post-Market Powers

Jul 01 2010

Takeda Uloric Cleared For Gout Indication

Feb 17 2009

Related Companies

Takeda Pharmaceutical Co. Ltd.

US WorldMeds, LLC

Novartis AG

Additional Topics

United States Advisory Committees Drug Safety Post Market Regulation & Studies Regulation Inflammation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window